Our Expert in China
No results available
China’s technology export-control framework requires exporters and cross-border transferors of certain sensitive technologies to engage with the Ministry of Commerce (MOFCOM) before an export or transfer proceeds. The framework is anchored in the Foreign Trade Law, the Regulations of the People’s Republic of China on the Administration of Technology Import and Export, and the Catalogue of Technologies Prohibited or Restricted from Export (administered jointly by MOFCOM and the Ministry of Science and Technology, MOST). For foreign investors, M&A teams and licensing managers, the practical consequences are significant: transactions touching artificial intelligence, biomedicine, photovoltaics and other listed technologies may require a licence, permit or filing with the authorities before closing.
This briefing explains which transactions are typically caught, how change of control is treated, what to build into contracts, and how the administrative process generally works.
Search-intent summary, compliance briefing. This is an actionable guide for foreign investors, buyers, sellers, licensees and deal teams. Four steps: (1) assess whether your transaction touches technology that may be listed in the restricted/prohibited catalogue; (2) determine the applicable licensing or filing requirement with MOFCOM; (3) amend closing conditions and licence agreements accordingly; (4) monitor official channels for amendments to the Catalogue and for any public consultations.
China regulates the cross-border transfer of technology principally through the Regulations on the Administration of Technology Import and Export and the Catalogue of Technologies Prohibited or Restricted from Export, which MOFCOM and MOST update from time to time. Technologies on the Catalogue fall into two tiers: “prohibited” technologies that may not be exported at all, and “restricted” technologies that may be exported only after obtaining a licence through MOFCOM’s administrative process. In addition, the Export Control Law (in force since 1 December 2020) provides an overarching statutory regime for controlled items, including certain technologies, data and related services.
Sensitive, strategically significant sectors, notably artificial intelligence, biomedicine and photovoltaics, have been the focus of recent revisions and public consultations on the Catalogue. For example, revisions have addressed items connected to large AI models, computing technologies, cell and gene therapy, pathogenic microorganisms, and polysilicon, wafer and cell manufacturing processes and key production equipment. The general effect is that cross-border transactions involving listed technology, including assignments, licences for use abroad, and changes in ownership or actual control where listed technology is involved, can require regulatory clearance before completion.
The reason this matters to deal teams is timing and structuring. A technology-export licensing requirement introduces a regulatory gate that must be sequenced ahead of, or as a condition to, completion. Teams should verify the current status of any relevant technology against the latest published Catalogue, because the treatment of specific technologies can change between consultation drafts and final text.
China’s framework defines its scope by reference to the cross-border movement of listed technology rather than the legal form of the deal. In practice, the licensing or filing trigger can reach several distinct transaction types: the assignment or transfer of ownership in a listed technology to a foreign entity; cross-border licensing of a domestic technology for use abroad; a change in the owner or actual controller of a Chinese technology holder where control passes to a foreign party; and other cases where core technology effectively leaves Chinese control.
Equally important is what typically sits outside the net. Technology already in the public domain, for example through open-source release or academic publication, may be excluded from certain restrictions, though the position depends on the precise Catalogue wording and the facts. Certain non-ownership licences and research collaborations may be treated more favourably. Any such carve-outs are narrow and fact-specific, so documentation of provenance and licence structure is essential before relying on an exclusion.
The following subsections unpack the main trigger categories and the practical questions each raises for inbound and outbound investors.
An outright assignment of ownership in a restricted technology to a foreign entity is a clear trigger for the export-control process. Where the technology is restricted, the required MOFCOM clearance should be obtained before the export or transfer takes effect; where it is prohibited, the transfer cannot lawfully proceed. Parties should review any assignment that has been signed but not fully performed, confirm the effective date of transfer, and maintain careful records of delivery milestones, data transmission and technical documentation hand-over. Where completion steps remain outstanding, treat clearance as a precondition to those steps rather than an afterthought.
Licensing arrangements require a sharper distinction than assignments. A licence that effectively transfers the right to exploit key listed technology abroad is likely to engage the export-control process, whereas a pure use-right that does not move ownership or core know-how may be treated differently. The analysis turns on substance: does the licence place the core technology, or the practical ability to reproduce and exploit it, in foreign hands? Where a biomedicine licence is purely for research and retains Chinese ownership, a more streamlined treatment may apply, but counsel should confirm the position against the current Catalogue and applicable regulations and document why the licence falls within any exclusion.
Transactions should be assessed for their substance, not merely their form as direct technology sales. Where the owner or actual controller of a Chinese technology holder changes such that control passes to a foreign party, regulators may examine whether the transaction effectively transfers the underlying technology. This elevates the concept of “actual controller”, a test that looks beyond nominal shareholding to who in substance directs the entity, into a central diligence question for any M&A, joint-venture exit or share sale involving a target that owns listed technology. A deal structured to avoid a formal IP assignment may still attract scrutiny if its practical effect is to hand foreign control over listed technology.
Separately, inbound acquisitions may also engage China’s foreign-investment security review regime, which is distinct from the technology export-control framework and should be assessed in parallel.
| Transaction type | Export-control clearance likely required? | Key caveats |
|---|---|---|
| IP assignment to foreign entity | Yes, if technology is restricted (prohibited if on the prohibited list) | Obtain clearance before export; review transfers begun but not completed |
| Exclusive licence for use abroad | Conditional, likely yes if it transfers the right to exploit key restricted tech abroad | Distinguish a licence transferring core technology from a pure use-right |
| Non-exclusive licence for research (no ownership transfer) | May benefit from more streamlined treatment | Depends on Catalogue wording and facts; retention of Chinese ownership is relevant |
| Change of control to a foreign controller | Potentially, may be assessed as an effective transfer | Depends on the “actual controller” test and whether tech control effectively moves; may also trigger FDI security review |
| Technical services / know-how supply abroad | Conditional | Depends on whether the service transfers core restricted technology |
For bidders and sellers, the change-of-control dimension of China’s technology controls reshapes deal risk. Where a target owns listed technology, a share sale or control transfer to a foreign party may require export-control clearance (and potentially foreign-investment security review) before completion, introducing a regulatory gate that may not exist for a straightforward equity deal. Buyers should begin with pre-deal screening to establish whether the target’s technology portfolio intersects with AI, biomedicine, photovoltaics or other restricted categories, and sellers should prepare disclosures that identify listed technology and any export history. Because these issues sit at the intersection of foreign investment and export control, sanctions and technology-transfer risk should be assessed together rather than in isolation.
Transaction structuring responds to this gate through familiar but recalibrated tools. Carve-outs can separate listed technology from the rest of a deal where commercially feasible. Escrow and holdbacks can protect a buyer against the risk that clearance is refused or delayed. Staggered or conditional closings can sequence the transaction so that completion of the sensitive element follows clearance. The common thread is treating regulatory clearance not as a post-closing formality but as a condition that governs whether and when control actually passes.
Diligence on a target that may hold listed technology should extend beyond a standard IP review. Key items include:
Contractual mechanisms should allocate the regulatory risk explicitly. Where a deal must pass through China’s technology export-control process, deal teams can deploy a layered set of protections:
Licence and technology-transfer agreements should address the export-control gate from the outset. The drafting objective is to prevent any export or transfer occurring before required clearance, to allocate responsibility for obtaining clearance clearly, and to preserve termination and remedy rights if the regime blocks performance. Representations and warranties should confirm the provenance and status of the technology; covenants should prohibit export or transfer without prior clearance; and assignment and change-of-control clauses should require notice and, where appropriate, consent so that a counterparty cannot trigger the regime unilaterally.
Territory and sublicence restrictions deserve particular attention, because the trigger turns on foreign use and foreign control. Audit rights allow a licensor to verify that a licensee has not exported beyond the permitted scope. Escrow of source code or technical documentation should be conditioned so that release does not itself constitute an unlicensed transfer. Delivery timing clauses should sequence hand-over after clearance, so that clearance becomes a precondition to any delivery milestone.
The following are drafting suggestions for counsel review only; they are not jurisdiction-specific and must be adapted and verified by a qualified PRC foreign-investment attorney before use.
For technologies classified as “restricted”, exporters must apply to the competent commerce authorities for a technology export licence before an export contract takes effect, following the procedure set out in the Regulations on the Administration of Technology Import and Export. Applications and related filings for technology trade are handled through MOFCOM’s channels, including its online systems. The general sequence is as follows:
Non-compliance carries enforcement risk. Exporting or transferring restricted technology without the required licence can expose parties to customs intervention at the border and to administrative and other penalties under the Export Control Law and the Regulations on the Administration of Technology Import and Export. Deal teams should therefore treat clearance as a hard precondition, not a parallel workstream.
Before beginning an application, assemble a data pack to avoid delays mid-submission. Parties should collect: full legal identity and registration details of the exporter or transferor; a precise technical description of the technology, including its classification against the Catalogue; the identity, jurisdiction and role of the foreign recipient or acquiring controller; the commercial structure of the transaction (assignment, licence, or control change); the intended export or transfer timeline and delivery milestones; and supporting provenance documentation, particularly for AI models that may qualify for an exclusion. Having this ready in a single template reduces the risk of an incomplete submission stalling a closing.
MOFCOM and MOST periodically publish proposed amendments to the Catalogue of Technologies Prohibited or Restricted from Export and open public consultations before finalising changes. Stakeholders who may be materially affected, technology owners, licensors, foreign acquirers and industry associations, should treat these windows as a genuine opportunity to shape the final scope. Consultation notices, deadlines and submission channels are published on the official MOFCOM and MOST websites, and parties should rely on those official notices for the applicable dates and procedures.
Effective submissions are targeted and technical. The most persuasive comments tend to propose narrowly drawn definitions, specific technical exclusions where a technology is already widely available, clearer treatment of non-ownership licences, and confidentiality protections for sensitive commercial information disclosed during the process. Coordinating submissions across an industry group, so that multiple stakeholders make a consistent, evidence-based case for particular clarifications, is generally more effective than isolated responses. Where a company’s concern is the breadth of a single listed item, a comment that proposes precise boundary language, supported by technical rationale, is more likely to influence the drafting than a general objection.
When the Catalogue is amended, technologies that are added to or remain on the restricted list move into, or stay within, the standard export licensing and permitting regime; technologies that are removed cease to be controlled under it. For some categories, notably non-ownership licences and research collaborations, the practical effect may be more streamlined treatment, but the applicable requirement depends on the final text. Until any amendment is finalised, the Catalogue as currently in force is the operative control.
Enforcement should not be underestimated. Exports of restricted technology without the required licence risk interception at the border and penalties under the technology export-control framework. Because regulators assess substance, parties cannot assume that a deal signed before an amendment is automatically grandfathered where performance remains outstanding; outstanding steps may be subject to the rules in force when they are performed. Deal teams should monitor the MOFCOM and MOST portals for amendments and refresh their compliance position when changes are published, because the treatment of specific technologies may shift between a consultation draft and the final text.
China’s technology export-control framework places AI, biomedicine, photovoltaics and other sensitive transactions within a licensing and compliance regime that deal teams must build into their structuring and timetable. Foreign investors should act early: screen transactions against the current Catalogue, obtain the applicable MOFCOM clearance before any export or transfer, rebuild closing conditions and licence terms around the regulatory gate, and engage with any open public consultation through official channels. Because the regime can capture deals already in progress and because the Catalogue is periodically amended, a proactive and well-documented approach is essential.
For transaction-specific advice, closing-condition drafting and consultation strategy, the Global Law Experts network can connect you with specialist China foreign investment counsel, see Sharon Zhu, Global Law Experts profile, the China Foreign Investment practice area, the China Foreign Investment lawyer directory, and the China export controls and technology transfer resources.
This article was produced by Global Law Experts. For specialist advice on this topic, contact Sharon Zhu at Hansheng Law Offices, a member of the Global Law Experts network.
posted 6 minutes ago
posted 26 minutes ago
posted 46 minutes ago
posted 53 minutes ago
posted 53 minutes ago
posted 53 minutes ago
posted 53 minutes ago
posted 54 minutes ago
posted 54 minutes ago
posted 54 minutes ago
posted 54 minutes ago
posted 54 minutes ago
No results available
Find the right Legal Expert for your business
Send welcome message